W

Walvax Biotechnology Co Ltd
SZSE:300142

Watchlist Manager
Walvax Biotechnology Co Ltd
SZSE:300142
Watchlist
Price: 12.76 CNY -2.45% Market Closed
Market Cap: 20.4B CNY
Have any thoughts about
Walvax Biotechnology Co Ltd?
Write Note
Walvax Biotechnology Co Ltd
/
Cash Flow Statement
/
Cash from Financing Activities

Walvax Biotechnology Co Ltd
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Walvax Biotechnology Co Ltd
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
W
Walvax Biotechnology Co Ltd
SZSE:300142
Cash from Financing Activities
¥152.8m
CAGR 3-Years
-42%
CAGR 5-Years
-21%
CAGR 10-Years
-19%
Beigene Ltd
HKEX:6160
Cash from Financing Activities
¥2.6B
CAGR 3-Years
-57%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Cash from Financing Activities
¥2.1B
CAGR 3-Years
-34%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash from Financing Activities
-¥893.3m
CAGR 3-Years
N/A
CAGR 5-Years
-98%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash from Financing Activities
-¥2B
CAGR 3-Years
24%
CAGR 5-Years
-38%
CAGR 10-Years
-39%
Imeik Technology Development Co Ltd
SZSE:300896
Cash from Financing Activities
-¥1.4B
CAGR 3-Years
N/A
CAGR 5-Years
-98%
CAGR 10-Years
N/A
No Stocks Found

Walvax Biotechnology Co Ltd
Glance View

Market Cap
20.5B CNY
Industry
Biotechnology

Nestled within China's burgeoning biotechnology sector, Walvax Biotechnology Co Ltd has emerged as a formidable player in the field of vaccine development and production. Founded in 2001, the company has adeptly positioned itself to address the pressing health care needs in China and beyond. As a modern biopharmaceutical manufacturer, Walvax combines cutting-edge research with robust manufacturing capabilities, focusing primarily on the development of human vaccines. Its portfolio encompasses vaccines for a variety of infectious diseases, including those that target influenza, pneumonia, and rotavirus, allowing it to carve out a significant niche in the industry. By leveraging partnerships with global research institutions and investing heavily in R&D, Walvax continually enhances its product offerings, ensuring that they remain at the forefront of vaccine technology. This concerted focus on innovation and quality allows Walvax not only to address the existing public health challenges but also to anticipate future needs. Financially, Walvax operates through a well-oiled revenue model primarily driven by its sales of vaccines to both domestic and international markets. The company has crafted a streamlined supply chain, ensuring wide accessibility and distribution of its products. Through strategic pricing and partnerships with healthcare providers and government agencies, Walvax ensures steady revenue inflows, enabling continued investment in research and expansion. With China's focus on improving health care infrastructure and rising global awareness regarding the importance of vaccines, Walvax finds itself in an advantageous position. The company's ability to swiftly respond to market demands and regulatory requirements has further solidified its status as a key contributor to public health and a linchpin in the fight against infectious diseases.

Intrinsic Value
15.65 CNY
Undervaluation 18%
Intrinsic Value
Price
W
What is Intrinsic Value?

See Also

What is Walvax Biotechnology Co Ltd's Cash from Financing Activities?
Cash from Financing Activities
152.8m CNY

Based on the financial report for Jun 30, 2024, Walvax Biotechnology Co Ltd's Cash from Financing Activities amounts to 152.8m CNY.

What is Walvax Biotechnology Co Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-19%

The average annual Cash from Financing Activities growth rates for Walvax Biotechnology Co Ltd have been -42% over the past three years , -21% over the past five years , and -19% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.